Clinical trial
GVAX in Advanced Prostate Cancer Patients Made Lymphopenic
NCT00122005 · Providence Health & Services, Other · Unknown status
Key facts
| NCT number | NCT00122005 |
|---|---|
| Title | GVAX in Advanced Prostate Cancer Patients Made Lymphopenic |
| Official title | Phase I/II Study of Human GM-CSF Gene-Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (GVAX®) in Advanced Prostate Cancer Patients Made Lymphopenic and Infused With Autologous Peripheral Blood Mononuclear Cells |
| Lead sponsor | Providence Health & Services, Other |
| Collaborators | Providence Cancer Center, Earle A. Chiles Research Institute Cell Genesys Industry |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | GM-CSF gene transduced allogeneic vaccine GVAX |
| Enrollment | 18 |
| Start date | Jul 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Jul 21, 2005 |
| Last update posted | Feb 24, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: